The Effect of Pentoxifylline on Erythrocyte Deformability and on Phosphatide Fatty Acid Distribution in the Erythrocyte Membrane

Schubotz, R; Mühlfellner, O

doi:10.1185/03007997709115279

Cited by 40 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 The exact mechanisms of action of PTX in improving microcirculatory flow and tissue oxygenation remain to be determined but may be 1) increase of erythrocyte deformability 13 - 16 by raising ATP content, 17 2) inhibition of platelet aggregation, 18 " 20 and 3) reduction of plasma fibrinogen concentrations. 21 These effects of PTX may contribute to the reduction of whole blood viscosity.…”

mentioning

confidence: 99%

Pentoxifylline in acute nonhemorrhagic stroke. A randomized, placebo-controlled double-blind trial.

Hsu

Norris

Hogan

et al. 1988

Stroke

View full text Add to dashboard Cite

The efficacy and safety of pentoxifylline were assessed in 297 adult patients with ischemic stroke in a molticenter, doable-blind, randomized and placebo-controlled trial. Treatment was started within 12 hoars after the stroke onset Study medication was administered intravenously continuously (16 mg/kg/day, maximum 1,200 mg/day) for 3 days and per os (400 mg ti.d.) for the remainder of 28 days. Demographic data were comparable, and functional impairment and mortality (pentoxifylline 12%, placebo 10%) were not different between the two groups. Neurologic deficit scores Improved from baseline admission scores during the 4-week study in both groups but did not differ between groups at admission or throughout the study except during the first few days when the consciousness level (Days 1 and 2), motor function (Days 1 and 2), cranial nerve function (Days 1-4), and total neurologic deficit scores (Days 1 and 2) were better in the pentoxifylline group than in the placebo group, especially in a subset of patients with severe deficits at admission. Laboratory values and side effects were also comparable between groups. Our study indicates that pentoxifylline can be given safely in patients with acute ischemic stroke. Although pharmacologk effects were present during the first few days, the clinical benefits were small and not sustained.

show abstract

mentioning

confidence: 99%

Pentoxifylline in acute nonhemorrhagic stroke. A randomized, placebo-controlled double-blind trial.

Hsu

Norris

Hogan

et al. 1988

Stroke

View full text Add to dashboard Cite

show abstract

“…A recent study demonstrated that the elastic modulus of RBC was decreased by Pentoxifylline treatment in vivo , which improved blood flow in subjects with cerebrovascular and peripheral arterial diseases ( Aifantis et al, 2019 ). Pentoxifylline is postulated to increase intracellular ATP concentrations, decrease Ca 2+ concentrations by activation of the Ca 2+ —Mg 2+ ATPase and calmodulin, and increase the phosphorylation of proteins into the RBC membrane ( Schubotz and Mühlfellner, 1977 ; Aifantis et al, 2019 ), which could increase RBC deformability. We previously demonstrated that tyrosine phosphorylation of membrane proteins was increased by the application of Pentoxifylline in vitro and was accompanied by an increase of RBC deformability in healthy donors ( Ugurel et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

A preliminary study of phosphodiesterases and adenylyl cyclase signaling pathway on red blood cell deformability of sickle cell patients

Goksel,

Ugurel,

Nader

et al. 2023

Front. Physiol.

View full text Add to dashboard Cite

Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by chronic anemia, intravascular hemolysis, and the occurrence of vaso-occlusive crises due to the mechanical obstruction of the microcirculation by poorly deformable red blood cells (RBCs). RBC deformability is a key factor in the pathogenesis of SCD, and is affected by various factors. In this study, we investigated the effects of adenylyl cyclase (AC) signaling pathway modulation and different phosphodiesterase (PDE) modulatory molecules on the deformability and mechanical stress responses of RBC from SCD patients (HbSS genotype) by applying 5 Pa shear stress with an ektacytometer (LORRCA). We evaluated RBC deformability before and after the application of shear stress. AC stimulation with Forskolin had distinct effects on RBC deformability depending on the application of 5 Pa shear stress. RBC deformability was increased by Forskolin before shear stress application but decreased after 5 Pa shear stress. AC inhibition with SQ22536 and protein kinase A (PKA) inhibition with H89 increased RBC deformability before and after the shear stress application. Non-selective PDE inhibition with Pentoxifylline increased RBC deformability. However, modulation of the different PDE types had distinct effects on RBC deformability, with PDE1 inhibition by Vinpocetine increasing deformability while PDE4 inhibition by Rolipram decreased RBC deformability after the shear stress application. The effects of the drugs varied greatly between patients suggesting some could benefit from one drug while others not. Developing drugs targeting the AC signaling pathway could have clinical applications for SCD, but more researches with larger patient cohorts are needed to identify the differences in the responses of sickle RBCs.

show abstract

“…Therefore, one might hypothesize that pentoxifylline affects red‐cell deformability. In rats receiving cyclosporine A, an immunosuppressant causing an increase in blood viscosity by a decrease in erythrocyte deformability, pentoxifylline was able to completely reverse these effects and thereby increase the glomerular filtration rate and renal plasma flow (19). A pentoxifylline‐induced increase in fatty acid composition of the red‐cell membrane has been hypothesized to be responsible for the improvement of red‐cell deformability.…”

Section: Discussionmentioning

confidence: 99%

Pentoxifylline attenuates the increase in whole blood viscosity after transfusion

Bacher

Eggensperger

Koppensteiner

et al. 2005

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

show abstract

The Effect of Pentoxifylline on Erythrocyte Deformability and on Phosphatide Fatty Acid Distribution in the Erythrocyte Membrane

Cited by 40 publications

References 9 publications

Pentoxifylline in acute nonhemorrhagic stroke. A randomized, placebo-controlled double-blind trial.

Pentoxifylline in acute nonhemorrhagic stroke. A randomized, placebo-controlled double-blind trial.

A preliminary study of phosphodiesterases and adenylyl cyclase signaling pathway on red blood cell deformability of sickle cell patients

Pentoxifylline attenuates the increase in whole blood viscosity after transfusion

Contact Info

Product

Resources

About